Rydapt
Chemical Name | midostaurin |
Dosage Form | Capsule (oral; 25 mg) |
Drug Class | Kinase inhibitors |
System | Blood |
Company | Novartis |
Approval Year | 2017 |
Indication
- To treat newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive in adults.
- To treat aggressive systemic mastocytosis in adults.
- To treat systemic mastocytosis with associated hematological neoplasm in adults.
- To treat mast cell leukemia in adults.